United Therapeutics (NASDAQ:UTHR – Get Free Report) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect United Therapeutics to post earnings of $6.16 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the company earned $5.24 earnings per share. United Therapeutics’s revenue was up 19.8% on a year-over-year basis. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.
United Therapeutics Stock Performance
Shares of UTHR opened at $348.65 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The stock has a 50-day moving average of $354.00 and a two-hundred day moving average of $313.31. The stock has a market cap of $15.46 billion, a P/E ratio of 16.48, a P/E/G ratio of 1.27 and a beta of 0.57. United Therapeutics has a one year low of $208.62 and a one year high of $377.03.
Insider Activity at United Therapeutics
Analysts Set New Price Targets
A number of equities research analysts recently commented on UTHR shares. Jefferies Financial Group upped their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. UBS Group increased their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Oppenheimer boosted their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $310.00 to $321.00 in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $361.33.
View Our Latest Stock Report on United Therapeutics
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
- Five stocks we like better than United Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks to Score from 40% YoY Data Center Capex Spending in 2025
- Top Biotech Stocks: Exploring Innovation Opportunities
- IBM Stock Has Never Looked So Exciting
- The Role Economic Reports Play in a Successful Investment Strategy
- GM’s Lithium Americas Deal Positions It for EV Dominance
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.